Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Status Not yet recruiting

Clinical Trial Summary

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06371417
Study type	Interventional
Source	Chugai Pharmaceutical
Contact	Clinical trials information
Phone	only use Email
Email	clinical-trials@chugai-pharm.co.jp
Status	Not yet recruiting
Phase	Phase 1
Start date	May 31, 2024
Completion date	June 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02868060` - Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)	Phase 1/Phase 2
Completed	`NCT04346654` - A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP	Phase 2
Terminated	`NCT01054443` - A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)	Phase 2
Recruiting	`NCT04915482` - TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies	Phase 2/Phase 3
Completed	`NCT00344149` - Rituximab as Second Line Treatment for ITP	Phase 3
Completed	`NCT04669600` - A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)	Phase 2
Completed	`NCT01666795` - Autoantibody Specificity and Response to IVIG in ITP	N/A
Active, not recruiting	`NCT05086744` - Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders	Phase 2
Recruiting	`NCT03951623` - The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients	Phase 1
Recruiting	`NCT04968899` - IgIV Plus Prednisone vs High-dose Dexamethasone for ITP	Phase 3
Recruiting	`NCT03975361` - Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)	N/A